Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus. - Wikidata - wikimedia - TriplyDB

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

http://www.wikidata.org/entity/Q37690751

about

Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.Antidiabetic Therapy in End-Stage Renal Disease.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.

P2860

Q36058592-5DED3C3D-C4E6-4055-9161-A4871BA6427A Q38433245-35B3F41B-2074-44E8-A2E8-FFA587606B42 Q38663903-2606BF09-BA40-46C3-92DB-8EE6CBF39D65

P2860

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

http://www.wikidata.org/entity/Q37690751

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

@en

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

@nl

type

label

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

@en

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

@nl

prefLabel

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

@en

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

@nl

P1433

Q37690751-81BE4186-B59D-462D-9BDC-18CB04303F8A

P1476

Q37690751-27BA0C72-B37A-44AC-AEB4-DBFE2D564C92

P2093

Q37690751-0BB3C0E9-E963-4BB0-BF90-F5C4EB7651C0

Q37690751-39BF0A1B-DBA8-47A2-8C3E-504812AEC60C

Q37690751-7A0C410E-6946-4ACB-9603-93807160EF22

Q37690751-859424DD-1F1E-45F6-85CA-87C66ECAFEC5

P2860

Q37690751-04B17425-AF76-4C9A-B722-B49874D9FB20

Q37690751-04DD6E07-0D21-44F8-BAAC-96CCE73E6911

Q37690751-099D8EBC-AFE9-4CB5-A9EB-180DD4F71DD7

Q37690751-0A1CFE94-A523-495B-BB4D-B1D6B96F8651

Q37690751-0CA5AB32-603A-4CB6-943F-2F80FA2C24F0

Q37690751-1C38056E-88A0-4AD6-B041-38C66C8FC7F4

Q37690751-1E4D0DD4-FF54-44A4-B8BD-7A3C10B82301

Q37690751-1E680262-26F3-4AFE-B612-FDEE5F762E25

Q37690751-2039A33A-5714-4C55-8F25-65C605509E22

Q37690751-277656A1-0EBA-469A-9CD9-11B856CBB5F1

P304

Q37690751-61D56366-6A19-4589-AF14-10FF197804A6

P31

Q37690751-BB3F5B93-69AA-4228-A9EB-03A41F74964D

P356

Q37690751-3E79E8A6-58D1-4136-902D-D29D460E85F1

P433

Q37690751-68078BD8-58C2-4B16-9C8F-DD26D48B7EDC

P478

Q37690751-BE6D71A8-5424-4D7C-9CC1-F8B9FC24C2C0

P577

Q37690751-DC115EBD-6888-4FE3-8E77-88BDCC3BBD17

P698

Q37690751-55127FF5-5425-4E9A-AC52-436D46339A37

P921

Q37690751-0E0D0302-24F3-4E6B-B99C-D588C6CBE4B5

P932

Q37690751-E7F1C2CB-F5AD-4AB6-A34B-B51AA5A8EDA5

P356

1947-2714.128471

P1433

North American journal of medical sciences

P1476

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

@en

P2093

Harmanjit Singh

http://www.w3.org/2001/XMLSchema#string

Jasbir Singh

http://www.w3.org/2001/XMLSchema#string

Pugazhenthan Thangaraju

http://www.w3.org/2001/XMLSchema#string

Shaveta Kaushal

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

Standards of medical care in diabetes--2012

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The sodium/glucose cotransport family SLC5

Active sugar transport in health and disease

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

P304

107-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/1947-2714.128471

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24741548

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3978932

http://www.w3.org/2001/XMLSchema#string